ADAP
Price
$0.26
Change
+$0.01 (+4.00%)
Updated
Jun 17, 04:59 PM (EDT)
Capitalization
67.93M
50 days until earnings call
PRME
Price
$1.61
Change
+$0.12 (+8.00%)
Updated
Jun 17, 04:59 PM (EDT)
Capitalization
212.04M
50 days until earnings call
Interact to see
Advertisement

ADAP vs PRME

Header iconADAP vs PRME Comparison
Open Charts ADAP vs PRMEBanner chart's image
Adaptimmune Therapeutics
Price$0.26
Change+$0.01 (+4.00%)
Volume$668
Capitalization67.93M
Prime Medicine
Price$1.61
Change+$0.12 (+8.00%)
Volume$72.85K
Capitalization212.04M
ADAP vs PRME Comparison Chart in %
Loading...
ADAP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ADAP vs. PRME commentary
Jun 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADAP is a Hold and PRME is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 18, 2025
Stock price -- (ADAP: $0.26 vs. PRME: $1.62)
Brand notoriety: ADAP and PRME are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ADAP: 39% vs. PRME: 299%
Market capitalization -- ADAP: $67.93M vs. PRME: $212.04M
ADAP [@Biotechnology] is valued at $67.93M. PRME’s [@Biotechnology] market capitalization is $212.04M. The market cap for tickers in the [@Biotechnology] industry ranges from $342.74B to $0. The average market capitalization across the [@Biotechnology] industry is $2.45B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ADAP’s FA Score shows that 0 FA rating(s) are green whilePRME’s FA Score has 0 green FA rating(s).

  • ADAP’s FA Score: 0 green, 5 red.
  • PRME’s FA Score: 0 green, 5 red.
According to our system of comparison, PRME is a better buy in the long-term than ADAP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ADAP’s TA Score shows that 5 TA indicator(s) are bullish while PRME’s TA Score has 5 bullish TA indicator(s).

  • ADAP’s TA Score: 5 bullish, 5 bearish.
  • PRME’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, PRME is a better buy in the short-term than ADAP.

Price Growth

ADAP (@Biotechnology) experienced а -7.57% price change this week, while PRME (@Biotechnology) price change was +4.19% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -4.14%. For the same industry, the average monthly price growth was +8.92%, and the average quarterly price growth was +2.18%.

Reported Earning Dates

ADAP is expected to report earnings on Aug 06, 2025.

PRME is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (-4.14% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PRME($212M) has a higher market cap than ADAP($67.9M). PRME YTD gains are higher at: -44.692 vs. ADAP (-52.812). ADAP has higher annual earnings (EBITDA): -50.18M vs. PRME (-200M). PRME has more cash in the bank: 144M vs. ADAP (59.6M). ADAP has less debt than PRME: ADAP (48.7M) vs PRME (121M). ADAP has higher revenues than PRME: ADAP (180M) vs PRME (3.85M).
ADAPPRMEADAP / PRME
Capitalization67.9M212M32%
EBITDA-50.18M-200M25%
Gain YTD-52.812-44.692118%
P/E RatioN/AN/A-
Revenue180M3.85M4,680%
Total Cash59.6M144M41%
Total Debt48.7M121M40%
FUNDAMENTALS RATINGS
ADAP vs PRME: Fundamental Ratings
ADAP
PRME
OUTLOOK RATING
1..100
534
VALUATION
overvalued / fair valued / undervalued
1..100
53
Fair valued
39
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9798
PRICE GROWTH RATING
1..100
9464
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PRME's Valuation (39) in the null industry is in the same range as ADAP (53) in the Biotechnology industry. This means that PRME’s stock grew similarly to ADAP’s over the last 12 months.

PRME's Profit vs Risk Rating (100) in the null industry is in the same range as ADAP (100) in the Biotechnology industry. This means that PRME’s stock grew similarly to ADAP’s over the last 12 months.

ADAP's SMR Rating (97) in the Biotechnology industry is in the same range as PRME (98) in the null industry. This means that ADAP’s stock grew similarly to PRME’s over the last 12 months.

PRME's Price Growth Rating (64) in the null industry is in the same range as ADAP (94) in the Biotechnology industry. This means that PRME’s stock grew similarly to ADAP’s over the last 12 months.

PRME's P/E Growth Rating (100) in the null industry is in the same range as ADAP (100) in the Biotechnology industry. This means that PRME’s stock grew similarly to ADAP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ADAPPRME
RSI
ODDS (%)
Bullish Trend 2 days ago
82%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
77%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
74%
Advances
ODDS (%)
Bullish Trend 19 days ago
77%
Bullish Trend 12 days ago
77%
Declines
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 6 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
ADAP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GOFIX18.62N/A
N/A
GMO Resources III
BGORX21.80N/A
N/A
BlackRock Advantage International R
NEEGX55.68N/A
N/A
Needham Growth Retail
FHUMX14.97N/A
N/A
Federated Hermes US SMID Institutional
GTLOX19.92-0.19
-0.94%
Glenmede Disciplined US Eq Ptf

PRME and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRME has been loosely correlated with CRSP. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if PRME jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRME
1D Price
Change %
PRME100%
+7.67%
CRSP - PRME
63%
Loosely correlated
+3.87%
BEAM - PRME
57%
Loosely correlated
+0.30%
RXRX - PRME
57%
Loosely correlated
-3.20%
CRBU - PRME
52%
Loosely correlated
+3.57%
VERV - PRME
50%
Loosely correlated
+81.50%
More